DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is looking at DNA in blood samples to see how well it predicts response to antibody therapy in patients with follicular lymphoma treated on clinical trials CALGB-50402 or CALGB-50701.
Genetic: gene expression analysis
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
|Official Title:||Natural Killer Cell KIR and HLA Genotypes May Predict Response to Antibody Therapy in Follicular Lymphoma|
- Association between killer immunoglobulin-like receptor (KIR) and HLA genotypes and 12-month overall response [ Designated as safety issue: No ]
- Association between KIR and HLA genotypes and survival outcomes [ Designated as safety issue: No ]
|Study Start Date:||February 2010|
|Estimated Primary Completion Date:||February 2011 (Final data collection date for primary outcome measure)|
- To test the hypothesis that killer immunoglobulin-like receptor (KIR) and HLA genotypes predict 12-month overall response (complete response, partial response, and unconfirmed complete response) in patients with follicular lymphoma treated with rituximab-containing monoclonal antibody combinations on CALGB-50402 or CALGB-50701.
- To test the hypothesis that KIR and HLA genotypes are associated with survival outcomes (progression-free and overall survival) in these patients.
OUTLINE: This is a multicenter study.
Genomic DNA is extracted from previously collected whole blood samples for killer immunoglobulin-like receptor (KIR) and HLA genotyping and polymorphism analysis.
|Principal Investigator:||Jeffrey M. Venstrom, MD||Memorial Sloan-Kettering Cancer Center|